IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-17446-4.html
   My bibliography  Save this article

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

Author

Listed:
  • Robert W. Cross

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Zachary A. Bornholdt

    (Mapp Biopharmaceutical Inc.)

  • Abhishek N. Prasad

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Joan B. Geisbert

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Viktoriya Borisevich

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Krystle N. Agans

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Daniel J. Deer

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Kevin Melody

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Karla A. Fenton

    (University of Texas Medical Branch
    University of Texas Medical Branch)

  • Heinz Feldmann

    (Laboratory of Virology, Division of Intramural Research, NIAID/NIH)

  • Armand Sprecher

    (Médecins Sans Frontières)

  • Larry Zeitlin

    (Mapp Biopharmaceutical Inc.)

  • Thomas W. Geisbert

    (University of Texas Medical Branch
    University of Texas Medical Branch)

Abstract

A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and humans when administered therapeutically. Uncertainty exists regarding the efficacy of postexposure antibody treatments in the event of a known exposure of a recent rVSV-ZEBOV vaccinee. Here, we model a worst-case scenario using rhesus monkeys vaccinated or unvaccinated with the rVSV-ZEBOV vaccine. We demonstrate that animals challenged with a uniformly lethal dose of EBOV one day following vaccination, and then treated with the anti-EBOV GP mAb MIL77 starting 3 days postexposure show no evidence of clinical illness and survive challenge. In contrast, animals receiving only vaccination or only mAb-based therapy become ill, with decreased survival compared to animals vaccinated and subsequently treated with MIL77. These results suggest that rVSV-ZEBOV augments immunotherapy.

Suggested Citation

  • Robert W. Cross & Zachary A. Bornholdt & Abhishek N. Prasad & Joan B. Geisbert & Viktoriya Borisevich & Krystle N. Agans & Daniel J. Deer & Kevin Melody & Karla A. Fenton & Heinz Feldmann & Armand Spr, 2020. "Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment," Nature Communications, Nature, vol. 11(1), pages 1-8, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17446-4
    DOI: 10.1038/s41467-020-17446-4
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-17446-4
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-17446-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17446-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.